GLPwatch
Papers (12034)
Page 182 of 201, ranked by citation count.
- Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling.
- Multimodal imaging reveals distinct cardiac benefits of dulaglutide versus dapagliflozin in a mouse model of glucotoxic cardiomyopathy.
- FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.
- Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
- A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
- Case study on adverse reactions of dulaglutide: literature review.
- Orforglipron, quand le GLP-1 devient simple et oral.
- Exendin-4 alleviates Aβ1-40-induced apoptosis and calcium dysregulation in RPE cells through the CHP1/NHE1 complex.
- Intense Uptake of 68 Ga-exendin-4 in a Patient With WHO Grade 3 Insulinoma and Extensive Intrahepatic Metastases.
- Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes.
- Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.
- Effects of liraglutide on gut bacterial community dynamics.
- Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series.
- The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.
- Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus.
- Commentary on the Risks of Prescription GLP-1 Agonists in Patients on Psychiatric Medications.
- Lixisenatide in the treatment of Type 2 diabetes.
- Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients.
- [Weight reduction with incretin mimetics-Opportunities and risks].
- Liraglutide Enhances Cell Viability and Reduces Oxidative Stress in Hyperglycemic H9c2 Cardiomyocytes.
- Exenatide administration time determines the effects on blood pressure dipping in <i>db/db</i> mice via modulation of food intake and sympathetic activity.
- Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity.
- The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
- Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.
- From Weight Loss to Organ-Specific Disease Modification: A Narrative Review of Incretin-Based Therapies in Obesity-Related Cardiometabolic Disease, Chronic Kidney Disease, Metabolic Dysfunction-Associated Steatohepatitis, and Obstructive Sleep Apnoea.
- Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States.
- Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
- Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.
- Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis.
- Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.
- [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
- Efficacy and Safety of Dulaglutide for Weight Reduction Among Diabetic Patients in Saudi Arabia: A Retrospective Cohort Study.
- Injections vs. Scalpels: Where Do Surgery and GLP-1's Align in Modern Obesity treatment?
- No evidence that tirzepatide can worsen diabetic retinopathy. Reply to Fadini GP [letter]. Reassessing retinopathy risk with tirzepatide therapy. Reply to Zhang N, Wang W, Wan G [letter].
- Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.
- Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.
- Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.
- Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.
- Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study".
- Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.
- Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation.
- Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review.
- SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.
- Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide.
- Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.
- Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
- [Weight Recurrence After Bariatric Surgery: Definitions, Diagnosis, and Management Strategies. Part 2].
- Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
- A systematic review of semaglutide-associated kidney injury case reports.
- Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
- Clinical Outcomes After Hospitalization for Acute Coronary Syndrome in Patients Treated with Semaglutide Versus Bariatric Surgery: A Retrospective Multicenter Analysis.
- Dulaglutide efficacy.
- REWIND Diabetes for Octogenarians.
- Change in circulating irisin level and its association with lipid metabolism after exenatide treatment in patients with type 2 diabetes mellitus.
- The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East.
- Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.
- Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.
- Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naïve and GLP-1RA Switch Initiation in a Retrospective Cohort.
- Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.
- The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.